ERBB2 and gastroesophageal junction adenocarcinoma: Furthermore, no grade 3 or 4 immune-related AEs occurred in cohort A. All these results suggested that the combination with immunotherapy is clinically safe and could be a treatment option for HER2-positive advanced GC or GEJ adenocarcinoma patients.